PDCD1 and melanoma: Consistent with the results previously reported for the dose‐escalation part,16 the final analysis of the study with additional follow‐up, including more patients with PD‐1 blockade–resistant melanoma, showed antitumor activity of vidutolimod as a single agent, as well as in combination with pembrolizumab.